We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BioNexus Gene Lab Corporation | NASDAQ:BGLC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0026 | 0.45% | 0.576501 | 0.573 | 0.58 | 0.5959 | 0.57 | 0.5959 | 11,097 | 15:29:27 |
Background:
Strategic Investment and Handover Ceremony:
Ceremony Participants:
Expanding Market Reach:
Digital Health & AI Market:
AISB’s Projections:
Quotes:
The handover ceremony took place at the Apollo Men’s Wellness Centre in Starhill, Kuala Lumpur on April 18th, 2024, witnessed by Mr. Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp (BGLC).
Photo:
Mr. Kenny Lai and Mr. CC Wong handing over the Letter of Offer to Mr. Andrew Teng and Mrs. Penny Attenbrough at Apollo Men’s Wellness Centre, witnessed by the CEO of BioNexus Gene Lab Corp., Mr. Sam Tan (centre)
About BioNexus Gene Lab Corporation:
BioNexus Gene Lab Corporation (NASDAQ: BGLC) is a global leader in RNA-based genomic diagnostics, committed to advancing personalized medicine and improving global health outcomes.
For more information, visit BioNexus Gene Lab Corp.’s website: www.bionexusgenelab.com
About Ascension Innovation Sdn Bhd:
Ascension Innovation Sdn Bhd (AISB) is at the forefront of healthcare technology, driving innovation through its flagship platform, aiCMS.
For more information, visit Ascension Innovation Sdn Bhd’s website: www.aisb.io
1 https://www.grandviewresearch.com/industry-analysis/digital-health-market2 https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market
For media inquiries, please contact:
Investor RelationsBioNexus Gene Lab CorporationEmail: ir@bionexusgenelab.com
Disclaimer:This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, and assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or projected. Forward-looking statements include, but are not limited to, statements regarding:
These forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially from the statements made. Such risks and uncertainties include, but are not limited to:
1. Market and Industry Risks:
- Rapidly evolving healthcare technology landscape
- Regulatory changes and compliance challenges
- Competitive pressures and market dynamics
2. Operational and Financial Risks:
- Execution of strategic initiatives
- Financial performance and liquidity
- Intellectual property protection
3. External Factors:
- Global economic conditions
- Public health crises (e.g., pandemics)
- Political and geopolitical uncertainties
Investors are cautioned not to place undue reliance on these forward-looking statements. BGLC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. The safe harbor provisions of the Private Securities Litigation Reform Act of 1995 protect forward-looking statements from litigation risks.
Investors are encouraged to review BGLC's filings with the Securities and Exchange Commission (SEC) for a comprehensive understanding of the company's business, financial performance, and risk factors.
BioNexus Gene Lab CorporationTower B, Vertical Business Suite 10-2No. 8, Jalan Kerinchi, Bangsar South,59200, Kuala Lumpur
Note to Editors: High-resolution images and additional information are available upon request.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3c3545c8-1c0f-47c1-aabc-7a3e4d1de620
1 Year BioNexus Gene Lab Chart |
1 Month BioNexus Gene Lab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions